Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Nov;33(11):1994–1997. doi: 10.1128/aac.33.11.1994

Influence of an antacid containing aluminum and magnesium on the pharmacokinetics of cefixime.

D P Healy 1, J V Sahai 1, L P Sterling 1, E M Racht 1
PMCID: PMC172801  PMID: 2610509

Abstract

Interaction studies in dogs have indicated that antacids significantly decrease the oral bioavailability of cefixime. Twelve healthy adult male volunteers participated in a randomized, four-way crossover trial to evaluate the influence of an aluminum-magnesium antacid (Maalox; 20 ml) on the pharmacokinetics of cefixime (400 mg). Regimens were (i) cefixime alone; (ii) cefixime simultaneous with antacid; (iii) cefixime 2 h before antacid; and (iv) cefixime 2 h after antacid. Serial blood and urine samples were collected over a 24-h period following each dose of cefixime. There was a 1-week washout interval between regimens. Cefixime concentrations in serum and urine were analyzed by high-performance liquid chromatography. Maximum cefixime concentrations in serum for regimens i through iv were (mean +/- standard deviation) 4.9 +/- 1.4, 5.7 +/- 1.3, 5.1 +/- 1.0, and 5.5 +/- 1.5 micrograms/ml, respectively. Corresponding values for area under the serum concentration-time curve extrapolated to infinity were 38.3 +/- 14.5, 42.8 +/- 13.9, 38.5 +/- 9.8, and 41.6 +/- 16.7 micrograms.h/ml. There was a trend toward increased concentrations in serum and area under the curve of cefixime when it was administered concomitantly with antacid; however, these differences were not statistically significant (P greater than 0.05; analysis of variance). We conclude that single-dose administration of an aluminum-magnesium antacid does not significantly decrease the oral bioavailability of cefixime.

Full text

PDF
1994

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barr W. H., Adir J., Garrettson L. Decrease of tetracycline absorption in man by sodium bicarbonate. Clin Pharmacol Ther. 1971 Sep-Oct;12(5):779–784. doi: 10.1002/cpt1971125779. [DOI] [PubMed] [Google Scholar]
  2. Falkowski A. J., Look Z. M., Noguchi H., Silber B. M. Determination of cefixime in biological samples by reversed-phase high-performance liquid chromatography. J Chromatogr. 1987 Nov 27;422:145–152. doi: 10.1016/0378-4347(87)80447-4. [DOI] [PubMed] [Google Scholar]
  3. Faulkner R. D., Bohaychuk W., Haynes J. D., Desjardins R. E., Yacobi A., Silber B. M. The pharmacokinetics of cefixime in the fasted and fed state. Eur J Clin Pharmacol. 1988;34(5):525–528. doi: 10.1007/BF01046715. [DOI] [PubMed] [Google Scholar]
  4. Faulkner R. D., Fernandez P., Lawrence G., Sia L. L., Falkowski A. J., Weiss A. I., Yacobi A., Silber B. M. Absolute bioavailability of cefixime in man. J Clin Pharmacol. 1988 Aug;28(8):700–706. doi: 10.1002/j.1552-4604.1988.tb03203.x. [DOI] [PubMed] [Google Scholar]
  5. Faulkner R. D., Yacobi A., Barone J. S., Kaplan S. A., Silber B. M. Pharmacokinetic profile of cefixime in man. Pediatr Infect Dis J. 1987 Oct;6(10):963–970. doi: 10.1097/00006454-198710000-00035. [DOI] [PubMed] [Google Scholar]
  6. Lode H. Drug interactions with quinolones. Rev Infect Dis. 1988 Jan-Feb;10 (Suppl 1):S132–S136. doi: 10.1093/clinids/10.supplement_1.s132. [DOI] [PubMed] [Google Scholar]
  7. Namiki Y., Tanabe T., Kobayashi T., Tanabe J., Okimura Y., Koda S., Morimoto Y. Degradation kinetics and mechanisms of a new cephalosporin, cefixime, in aqueous solution. J Pharm Sci. 1987 Mar;76(3):208–214. doi: 10.1002/jps.2600760305. [DOI] [PubMed] [Google Scholar]
  8. Neu H. C., Chin N. X., Labthavikul P. Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin. Antimicrob Agents Chemother. 1984 Aug;26(2):174–180. doi: 10.1128/aac.26.2.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Neuvonen P. J. Interactions with the absorption of tetracyclines. Drugs. 1976;11(1):45–54. doi: 10.2165/00003495-197611010-00004. [DOI] [PubMed] [Google Scholar]
  10. Sommers D. K., van Wyk M., Moncrieff J., Schoeman H. S. Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. Br J Clin Pharmacol. 1984 Oct;18(4):535–539. doi: 10.1111/j.1365-2125.1984.tb02501.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Tsuji A., Terasaki T., Tamai I., Hirooka H. H+ gradient-dependent and carrier-mediated transport of cefixime, a new cephalosporin antibiotic, across brush-border membrane vesicles from rat small intestine. J Pharmacol Exp Ther. 1987 May;241(2):594–601. [PubMed] [Google Scholar]
  12. Welling P. G. Interactions affecting drug absorption. Clin Pharmacokinet. 1984 Sep-Oct;9(5):404–434. doi: 10.2165/00003088-198409050-00002. [DOI] [PubMed] [Google Scholar]
  13. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978 Apr;6(2):165–175. doi: 10.1007/BF01117450. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES